Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

Moretto, T.; Milton, Denái R.; Ridge, Terry; MacConell, Leigh; Okerson, Ted; Wolka, Anne M.; Brodows, Robert G.

doi:10.1016/j.clinthera.2008.08.006

Cited by 321 publications

(349 citation statements)

References 28 publications

Supporting

Mentioning

328

Contrasting

Unclassified

Order By: Relevance

“…GLP-1 and its analogs have been demonstrated to reduce food intake and decrease the body weight in diabetic animal models and clinical studies [37][38][39] . Inhibition of DPP-4 activity prevented degradation and enhanced the biological activity of active GLP-1 [15] .…”

Section: Discussionmentioning

confidence: 99%

Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models

et al. 2012

View full text Add to dashboard Cite

Aim: Dipeptidyl deptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic agents. The purpose of this study was to assess the acute and chronic effects of SHR117887, a novel DPP-4 inhibitor, on metabolic control and pancreatic β-cell function in normal or diabetic rodent models. Methods: In the acute experiments, ICR mice, diet-induced obese (DIO) rats and ob/ob mice were subjected to an oral glucose tolerance test (OGTT) following a single oral administration of SHR117887 (0.1, 0.3, 1, or 3 mg/kg). Blood samples were collected to measure glucose, insulin, DPP-4 activity and active GLP-1 level. In the chronic experiments, ob/ob mice was administered SHR117887 (3, 10, or 30 mg/kg) twice daily for 33 d to assess the effects on metabolic control and pancreatic β-cell function. Vildagliptin (LAF237) was used as a positive control in all the experiments. Results: Acute oral administration of SHR117887 dose-dependently decreased the serum DPP-4 activity and improved glucose tolerance in ICR mice, DIO rats and ob/ob mice. This was accompanied by significant increases in the serum active GLP-1 and insulin levels. Chronic administration of SHR117887 significantly decreased fasting blood glucose level and improved the lipid profiles in ob/ob mice by reducing the serum triglyceride and free fatty acid levels, and its efficacy was comparable with that of vildagliptin at the same molarity. Moreover, chronic administration of SHR117887 increased the insulin staining of islet cells, which is suggestive of improved β-cell function. Conclusion: SHR117887 is a potent DPP-4 inhibitor that improves metabolic control and β-cell function in diabetic rodent models, suggesting that it could be a new therapeutic agent for the treatment of type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models

et al. 2012

View full text Add to dashboard Cite

show abstract

“…46 In patients receiving ongoing metformin, sulfonylurea, or thiazolidinedione (TZD) treatment, the response to exenatide was, similar, ranging from -0.4% to -1.2%. [52][53][54]56 The core clinical trials of exenatide ranged from 16-30 weeks in duration.…”

Section: Clinical Studiesmentioning

confidence: 99%

“…55 A notable benefit of GLP-1 therapy is its positive impact on weight. Mean, significant weight loss with exenatide ranged from -0.9 kg to -4.2 kg in shortterm studies, 46,47,[49][50][51][52][53][54][55][56]59 which was significantly greater than placebo in all but one study. 49 The open label extension trials demonstrated that weight loss with exenatide appears to be progressive with patients losing from -3.3 kg to -5.3 kg total weight loss over the 82-week period, versus -0.9 kg to -2.8 kg at the end of the 26-week placebo controlled phase.…”

Section: Clinical Studiesmentioning

confidence: 99%

“…47,[53][54][55]59 Many clinical trials also measured exenatide's effect on postprandial glucose levels. 46,47,[50][51][52][53][54][55][56]59 Exenatide demonstrated a significantly greater reduction in postprandial glucose concentration than placebo or insulin in all but one of the trials in which postprandial glucose was measured. In the remaining study, biphasic insulin demonstrated lower postprandial glucose concentrations than exenatide.…”

Section: Clinical Studiesmentioning

confidence: 99%

“…[37][38][39][40][41][42] Furthermore, exenatide has also shown to have a positive effect on blood pressure in hypertensive patients, 37,38,43 but there are no consistent trends in regards to exenatide's effect on lipids. [44][45][46][47][48] Numerous studies have compared exenatide to placebo [49][50][51][52] or insulin 47,[53][54][55] in patients receiving metformin and/or sulfonylureas. Over all of the studies, patients receiving exenatide had significant reductions in HbA1c ranging from -0.4% to -1.2%, and all reductions were significantly greater than placebo.…”

Section: Clinical Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes

Bellows

Hunter²,

McAdam‐Marx³

2011

Clinical Medicine Reviews in Vascular Health

View full text Add to dashboard Cite

Abstract:Exenatide was the first glucagon like peptide-1 (GLP-1) agonist approved for treatment in patients with type 2 diabetes. Clinical trials and real-world studies of exenatide, a subcutaneous injection given twice per day, indicate that it significantly reduces hemoglobin A1c values and weight with a low risk of hypoglycemia. Exenatide is generally well tolerated, but transient nausea and vomiting are commonly occurring side effects. Given this profile, exenatide has been shown to be cost effective relative to insulin glargine. Thus, exenatide is a treatment option that should be considered for patients with type 2 diabetes that is uncontrolled on one or more oral agents and for which additional weight gain and hypoglycemia are undesirable.

show abstract

Glucagon-like peptide analogues for type 2 diabetes mellitus

Shyangdan

Royle

Clar³

et al. 2011

Cochrane Database of Systematic Reviews

179

131

View full text Add to dashboard Cite

Publisher statement: This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2011, Issue 10. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.' Shyangdan, D.S. et al. (2011). Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD006423.

show abstract

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

Cited by 321 publications

References 28 publications

Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models

Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models

Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes

Glucagon-like peptide analogues for type 2 diabetes mellitus

Contact Info

Product

Resources

About